Treatment for Recurrent Nasopharynx Cancer (NPC)
Occasionally after radiotherapy for NPC, local recurrence of disease may occur in the nasopharynx, with no evidence of disease elsewhere in the body, called metastases.

There is evidence that re-treatment may lead to long term control, especially if the recurrence occurs greater than two years from completion of initial treatment.

Cyberknife is particularly appealing for treating recurrent disease due to dose conformality the treatment offers, so critical in the setting of re-irradiation. Re-treatment is considered high risk due to risk of tissue damage, and sparing of surrounding normal tissue in the setting of attempted salvage treatment is of utmost importance.